By Deena Beasley

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine’s proven effectiveness.

CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said.

Current HIV prevention recommendations from the U.S. Preventive Services Task Force (USPSTF), which is supported by HHS, include only three older drugs.

A source familiar with the situation suggested that G

See Full Page